Please ensure Javascript is enabled for purposes of website accessibility

When Will We Have a Flu/COVID-19 Vaccine Combo?

By Taylor Carmichael - Updated Jun 26, 2021 at 10:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax has already found its molecule and its animal trial data is excellent.

Novavax (NVAX 2.92%) was one of the top stocks in the entire stock market in 2020, running up from $4 a share on Jan. 2 all the way to $119 a share by Dec. 31. It had this magnificent run as Wall Street became more and more convinced that the company's COVID-19 vaccine would make a lot of money. And while Novavax's vaccine still hasn't been approved by the Food and Drug Administration (FDA), many investors remain bullish that it will be soon.

The stock market, however, is a forward-looking mechanism. So what's in the pipeline? Novavax also has a flu vaccine with great phase 3 data. Investors are expecting that drug to also win FDA approval. But what's tantalizing for long-term shareholders are the company's plans for vaccination over the next decade. In this video from Motley Fool Live, recorded on May 14, Corinne Cardina, healthcare and cannabis bureau chief at Fool.com, and Motley Fool writer Taylor Carmichael discuss the prospects for a COVID-19/Flu combo shot. 

Corinne Cardina: Let's talk a little bit more about Novavax. So you mentioned this is one of the companies that is supplying the third world. They're sending doses to COVAX. What is the latest with Novavax? They had said that they might be able to combine the flu and the COVID vaccine. What is the timeline and probability that something like that actually comes to fruition?

Taylor Carmichael: That's very exciting. I think for all investors really. They just released their animal data. They've already found their molecule. They've already combined their flu vaccine with their COVID-19 vaccine, which both those vaccines are highly successful. They've combined them and now they have to test it all over again. So it's not just a matter of putting two vaccines together in one shot, you have to test it again but what they are happy to see is they've gotten the same response in ferrets and hamsters that they had before. They had a huge number of antibodies created. They saw no signs -- they introduced COVID-19 into these animals -- they saw no signs of it reproducing. They saw no signs of pneumonia in the lungs. It was a really good release of data and they're going to start human trials later this year. It probably will not be as fast as the COVID-19 vaccines, I don't think the FDA is going to do that super accelerated pathway. I would not expect that drug to hit the market in a year. I wouldn't expect that at all, but possibly in 2022, but more likely 2023. I think it's highly likely that you can start seeing combo vaccines in the market. You will see Novavax's and Moderna's also pursuing this, and that's, I think, where the future is going to be. The future is going to be people going to get their flu vaccine and they're going to get COVID vaccine, and they're going to get the same shot.

Corinne Cardina owns shares of Moderna Inc. Taylor Carmichael owns shares of Novavax. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$41.52 (2.92%) $1.18
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$169.71 (-1.22%) $-2.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
389%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.